SCHEMBL30859784

SCHEMBL30859784

CC(C)(C)OC(=O)N1CC(C(=O)N2CCN(c3ncc(C(F)(F)F)cn3)CC2)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 9/20 0.50
TIPARP Q7Z3E1 3/20 0.48
TNKS O95271 1/20 0.48
PARP14 Q460N5 1/20 0.48
PARP10 Q53GL7 1/20 0.48
PARP12 Q9H0J9 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
PARP11 Q9NR21 1/20 0.48
PARP2 Q9UGN5 1/20 0.48
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.44
PARP1 P09874 1/20 0.44
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
PTPN11 Q06124 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MC4R P32245 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29169128 0.92 GPR119 (0.50) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL29168944 0.92 GPR119 (0.50) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL29168949 0.92 GPR119 (0.50) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL31410440 0.91 HPGD (0.48) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL31381854 0.91 HPGD (0.48) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL31410468 0.90 HPGD (0.55) GPR119MAPTHPGDPARP1SMN1; SMN2
SCHEMBL21521091 0.89 GPR119 (0.60) GPR119TIPARPMAPTHPGDPPARG
SCHEMBL31381898 0.86 GPR119 (0.46) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL30860096 0.86 GPR119 (0.48) GPR119TIPARPTNKSPARP14PARP10
SCHEMBL31381853 0.86 SMN1; SMN2 (0.61) TIPARPMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 US disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 EP disclosed
CN-119968364-A Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds 阿兹卡拉疗法公司 2025-05-09 CN disclosed
WO-2025045246-A1 PARP7 INHIBITOR AND USE THEREOF 重庆华森英诺生物科技有限公司 2025-03-06 WO disclosed
CN-119330972-A PARP7 inhibitor and application thereof 重庆华森英诺生物科技有限公司 2025-01-21 CN disclosed
WO-2024073133-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 GPR119 3786/4885TIPARP 1314/4885TNKS 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.